StockData
Rocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc. (RCKT) stock

RCKTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 3/30
$2.11+0.00 (0.00%)

Close on Nov 18, 2026Market cap $231.62MP/E –Yield –

Rocket Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Rocket Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$170.27M. For fiscal 2025 it was -$190.01M. The highest annual figure on record is -$5.50M in fiscal 2016.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$190.01M–
FY2024Dec 31, 2024-$209.72M–
FY2023Dec 31, 2023-$194.92M–
FY2022Dec 31, 2022-$178.14M–
FY2021Dec 31, 2021-$121.16M–
FY2020Dec 31, 2020-$74.64M–
FY2019Dec 31, 2019-$64.66M–
FY2018Dec 31, 2018-$53.79M–
FY2017Dec 31, 2017-$15.96M–
FY2016Dec 31, 2016-$5.50M–
FY2015Dec 31, 2015-$17.42M–
FY2014Dec 31, 2014-$9.74M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$39.61M–
Q1 FY2026Mar 31, 2026-$45.39M–
Q4 FY2025Dec 31, 2025-$34.84M–
Q3 FY2025Sep 30, 2025-$50.42M–
Q2 FY2025Jun 30, 2025-$48.96M–
Q1 FY2025Mar 31, 2025-$55.79M–
Q4 FY2024Dec 31, 2024-$46.94M–
Q3 FY2024Sep 30, 2024-$52.10M–
Q2 FY2024Jun 30, 2024-$53.82M–
Q1 FY2024Mar 31, 2024-$56.86M–
Q4 FY2023Dec 31, 2023-$29.34M–
Q3 FY2023Sep 30, 2023-$57.15M–
Q2 FY2023Jun 30, 2023-$50.87M–
Q1 FY2023Mar 31, 2023-$57.56M–
Q4 FY2022Dec 31, 2022-$56.02M–
Q3 FY2022Sep 30, 2022-$43.86M–
Q2 FY2022Jun 30, 2022-$39.04M–
Q1 FY2022Mar 31, 2022-$39.22M–
Q4 FY2021Dec 31, 2021-$30.94M–
Q3 FY2021Sep 30, 2021-$27.41M–
Q2 FY2021Jun 30, 2021-$38.53M–
Q1 FY2021Mar 31, 2021-$24.28M–
Q4 FY2020Dec 31, 2020-$13.11M–
Q3 FY2020Sep 30, 2020-$17.25M–
Q2 FY2020Jun 30, 2020-$22.03M–
Q1 FY2020Mar 31, 2020-$22.25M–
Q4 FY2019Dec 31, 2019-$19.73M–
Q3 FY2019Sep 30, 2019-$10.85M–
Q2 FY2019Jun 30, 2019-$18.10M–
Q1 FY2019Mar 31, 2019-$15.98M–
Q4 FY2018Dec 31, 2018-$20.81M–
Q3 FY2018Sep 30, 2018-$11.64M–
Q2 FY2018Jun 30, 2018-$9.74M–
Q1 FY2018Mar 31, 2018-$11.60M–
Q4 FY2017Dec 31, 2017-$5.99M-129.0%
Q3 FY2017Sep 30, 2017-$4.09M–
Q2 FY2017Jun 30, 2017-$2.16M–
Q1 FY2017Mar 31, 2017-$3.72M–
Q4 FY2016Dec 31, 2016$20.63M–
Q3 FY2016Sep 30, 2016-$9.13M–

More Rocket Pharmaceuticals figures

See a number that looks wrong?